A randomized controlled trial evaluated the MyPal eHealth platform’s impact on quality of life among patients with chronic lymphocytic leukemia and myelodysplastic syndromes, revealing significant...
Adults 66 years and older with CLL who began treatment with a Bruton’s tyrosine kinase inhibitor were more likely to discontinue early, require subsequent therapy, and experience hospitalization compared...
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
Researchers who developed a meta-analysis of 19 randomized controlled trials found a statistically significant improvement in overall survival with sorafenib when compared with placebo for patients with...
The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
